SEHK:2157Biotechs
Lepu Biopharma (SEHK:2157) Stock Grapples With Profit Quality Concerns
Lepu Biopharma came into today on the back foot, with the stock down about 10% over the past month, and investors clearly questioning whether the earlier move into profitability can hold. The latest half year report now forces a sentiment reset. Revenue for H1 2026 reached C¥522.4m, yet net income from core operations was only C¥27.4m, a sharp contrast with the recent trailing figures that were lifted by a C¥290.4m one off gain.
The market reaction looks less like cool analysis and more like...